Whitehawk Therapeutics (NASDAQ:WHWK) Rating Increased to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Whitehawk Therapeutics from “sell” to “hold.” Despite this, the broader analyst consensus remains “Moderate Buy,” with six Buy ratings, one Hold and one Sell, and an average price target of $8.20.
• Whitehawk shares opened at $4.76, compared with a 52-week range of $1.57 to $5.49. The company recently reported a quarterly loss of $0.20 per share, beating analysts’ expected loss of $0.30.
• Institutional investors and hedge funds own approximately 52.08% of the stock, with several firms recently initiating or expanding positions.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday.

Several other research firms have also recently weighed in on WHWK. Citigroup initiated coverage on Whitehawk Therapeutics in a research note on Thursday, April 16th. They set an "outperform" rating for the company. Leerink Partners started coverage on shares of Whitehawk Therapeutics in a report on Monday, July 13th. They set an "outperform" rating and a $9.00 price objective on the stock. Oppenheimer restated an "outperform" rating and set a $7.00 price objective on shares of Whitehawk Therapeutics in a research report on Friday, May 8th. Weiss Ratings cut shares of Whitehawk Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a report on Friday, June 5th. Finally, Citizens Jmp assumed coverage on shares of Whitehawk Therapeutics in a research report on Thursday, April 16th. They issued a "market outperform" rating and a $8.00 target price on the stock. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $8.20.

Whitehawk Therapeutics Price Performance

Whitehawk Therapeutics stock opened at $4.76 on Friday. Whitehawk Therapeutics has a 1-year low of $1.57 and a 1-year high of $5.49. The stock has a market cap of $235.38 million, a PE ratio of -4.25 and a beta of 0.76. The stock's fifty day moving average is $4.11 and its two-hundred day moving average is $3.78.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10. On average, research analysts expect that Whitehawk Therapeutics will post -1.37 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Eversept Partners LP purchased a new stake in Whitehawk Therapeutics during the 4th quarter valued at approximately $630,000. Bank of New York Mellon Corp purchased a new stake in shares of Whitehawk Therapeutics in the second quarter valued at about $378,000. Bank of America Corp DE increased its stake in shares of Whitehawk Therapeutics by 12,761.6% during the first quarter. Bank of America Corp DE now owns 52,861 shares of the company's stock worth $182,000 after acquiring an additional 52,450 shares during the period. Quadrature Capital Ltd acquired a new position in shares of Whitehawk Therapeutics during the fourth quarter worth about $28,000. Finally, Marshall Wace LLP purchased a new position in shares of Whitehawk Therapeutics during the 4th quarter worth approximately $164,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source